Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) CFO Crispina Calsada sold 38,716 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,782.16. Following the transaction, the chief financial officer now directly owns 50,566 shares in the company, valued at approximately $63,713.16. This represents a 43.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of NASDAQ:RGLS traded up $0.05 during midday trading on Wednesday, hitting $1.27. 283,082 shares of the company's stock traded hands, compared to its average volume of 348,120. The firm's fifty day moving average price is $1.53 and its two-hundred day moving average price is $1.59. Regulus Therapeutics Inc. has a twelve month low of $1.08 and a twelve month high of $3.79. The company has a market cap of $83.19 million, a PE ratio of -1.19 and a beta of 1.60.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). As a group, equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in shares of Regulus Therapeutics in the second quarter valued at $352,000. Rhumbline Advisers acquired a new position in Regulus Therapeutics in the 2nd quarter worth $136,000. Renaissance Technologies LLC boosted its position in Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company's stock valued at $211,000 after buying an additional 42,600 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics during the third quarter valued at about $33,000. Finally, Creative Planning purchased a new stake in shares of Regulus Therapeutics during the third quarter worth about $26,000. Institutional investors and hedge funds own 92.38% of the company's stock.
Several research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. StockNews.com upgraded Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $10.80.
Check Out Our Latest Research Report on RGLS
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.